Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | -0.43 | -0.07 | -0.11 |
| FCF Yield | -1.66% | -4.10% | -5.27% | -5.33% |
| EV / EBITDA | -17.33 | -15.81 | -9.37 | -7.43 |
| Quality | ||||
| ROIC | -7.77% | -53.62% | -37.47% | -33.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.71 | 0.95 | 0.89 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 46.15% | -37.42% | -2.58% | 41.20% |
| Safety | ||||
| Net Debt / EBITDA | 14.18 | 1.67 | 2.86 | 3.07 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -54,609.85 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |